Dec 02, 2015 Press Release for Alnylam
Alnylam to Webcast R&D Day
Dec 02, 2015
Alnylam management and leading physicians will discuss development candidates from the company's RNAi therapeutics pipeline. The event will include presentations from the following guest speakers:
-
Guy Young , M.D.
Director of Hemostasis & Thrombosis Center at Children's Hospital Los Angeles and Professor of Pediatrics atUniversity of Southern California Keck School of Medicine
-
Robert Desnick , M.D., Ph.D.
Dean for Genetic & Genomic Medicine, Professor & Chair Emeritus at Icahn School of Medicine atMount Sinai
-
Anita Hill , MBChB (Hons), MRCP, FRCPath, Ph.D.
Consultant Haematologist forLeeds Teaching Hospitals NHS Trust ,UK , and Honorary Senior Lecturer at the University of Leeds
The meeting will be held on
About
Alnylam is a biopharmaceutical
company developing novel therapeutics based on RNA interference, or
RNAi. The company is leading the translation of RNAi as a new class of
innovative medicines. Alnylam's pipeline of investigational RNAi
therapeutics is focused in 3 Strategic Therapeutic Areas (STArs):
Genetic Medicines, with a broad pipeline of RNAi therapeutics for the
treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of
RNAi therapeutics toward genetically validated, liver-expressed disease
targets for unmet needs in cardiovascular and metabolic diseases; and
Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance
for the advancement and commercialization of RNAi therapeutics as a
whole new class of innovative medicines. Specifically, by the end of
2020, Alnylam expects to achieve a company profile with 3 marketed
products, 10 RNAi therapeutic clinical programs - including 4 in late
stages of development - across its 3 STArs. The company's demonstrated
commitment to RNAi therapeutics has enabled it to form major alliances
with leading companies including
View source version on businesswire.com: http://www.businesswire.com/news/home/20151202005150/en/
(Investors and Media)
or
(Investors)
Source:
News Provided by Acquire Media
For Media Inquiries, please contact:
Christine Akinc
Chief Corporate Communications Officer media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam